Serum MicroRNAs: A New Diagnostic Method for Colorectal Cancer

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2014 Mar 21

PMID 24648974

Citations 19

Authors

Yi Yang

Xiaodong Gu

Minwei Zhou

Jianbin Xiang

Zongyou Chen

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the third most common malignant tumor worldwide, affecting over 1.23 million individuals annually. Over the past several years, the role of microRNAs (miRNAs) in CRC cells have been extensively investigated. Recently, it was discovered that extracellular miRNAs circulate in the blood of healthy individuals as well as CRC patients. Serum circulating miRNAs as novel biomarkers may be a new approach to CRC diagnosis. However, their secretory mechanism and biological function have not been fully elucidated. In this review, the main serum miRNAs used as potential diagnostic biomarkers for CRC, such as miR-92, miR-141, miR-29a, miR-21, miR-221, miR-601 and miR-760, were summarized. In addition, the mechanism of miRNA secretion from CRC cells was discussed. It is recommended that additional studies focus on the usefulness of serum miRNAs for early CRC diagnosis, prognosis and therapeutics.

Citing Articles

miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway.

Du H, Wang X, Dong R, Hu D, Xiong Y Int J Clin Exp Pathol. 2020; 12(12):4361-4379.

PMID: 31933840 PMC: 6949885.

The Differential DNA Hypermethylation Patterns of microRNA-137 and microRNA-342 Locus in Early Colorectal Lesions and Tumours.

Kashani E, Hadizadeh M, Chaleshi V, Mirfakhraie R, Young C, Savabkar S Biomolecules. 2019; 9(10).

PMID: 31546665 PMC: 6843302. DOI: 10.3390/biom9100519.

Exosome: Function and Role in Cancer Metastasis and Drug Resistance.

Zhang C, Ji Q, Yang Y, Li Q, Wang Z Technol Cancer Res Treat. 2018; 17:1533033818763450.

PMID: 29681222 PMC: 5949932. DOI: 10.1177/1533033818763450.

MiR-760 suppresses human colorectal cancer growth by targeting BATF3/AP-1/cyclinD1 signaling.

Cao L, Liu Y, Wang D, Huang L, Li F, Liu J J Exp Clin Cancer Res. 2018; 37(1):83.

PMID: 29661228 PMC: 5902951. DOI: 10.1186/s13046-018-0757-8.

Cell-autonomous and cell non-autonomous downregulation of tumor suppressor DAB2IP by microRNA-149-3p promotes aggressiveness of cancer cells.

Bellazzo A, Di Minin G, Valentino E, Sicari D, Torre D, Marchionni L Cell Death Differ. 2018; 25(7):1224-1238.

PMID: 29568059 PMC: 6030048. DOI: 10.1038/s41418-018-0088-5.

References

Skog J, Wurdinger T, van Rijn S, Meijer D, Gainche L, Sena-Esteves M . Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10(12):1470-6. PMC: 3423894. DOI: 10.1038/ncb1800. View

Kosaka N, Iguchi H, Ochiya T . Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010; 101(10):2087-92. PMC: 11159200. DOI: 10.1111/j.1349-7006.2010.01650.x. View

Chim S, Shing T, Hung E, Leung T, Lau T, Chiu R . Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54(3):482-90. DOI: 10.1373/clinchem.2007.097972. View

Ahmed F, Vos P, Jeffries C, Wiley J, Weidner D, Mota H . Differences in mRNA and microRNA microarray expression profiles in human colon adenocarcinoma HT-29 cells treated with either Intensity-modulated Radiation Therapy (IMRT), or Conventional Radiation Therapy (RT). Cancer Genomics Proteomics. 2009; 6(2):109-27. View

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

Amayo A, Kuria J . Clinical application of tumour markers: a review. East Afr Med J. 2011; 86(12 Suppl):S76-83. DOI: 10.4314/eamj.v86i12.62909. View

Zernecke A, Bidzhekov K, Noels H, Shagdarsuren E, Gan L, Denecke B . Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009; 2(100):ra81. DOI: 10.1126/scisignal.2000610. View

Pu X, Huang G, Guo H, Guo C, Li H, Ye S . Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol. 2010; 25(10):1674-80. DOI: 10.1111/j.1440-1746.2010.06417.x. View

Wang Q, Huang Z, Ni S, Xiao X, Xu Q, Wang L . Plasma miR-601 and miR-760 are novel biomarkers for the early detection of colorectal cancer. PLoS One. 2012; 7(9):e44398. PMC: 3435315. DOI: 10.1371/journal.pone.0044398. View

10.

Slaby O, Svoboda M, Michalek J, Vyzula R . MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009; 8:102. PMC: 2780389. DOI: 10.1186/1476-4598-8-102. View

11.

Visone R, Croce C . MiRNAs and cancer. Am J Pathol. 2009; 174(4):1131-8. PMC: 2671346. DOI: 10.2353/ajpath.2009.080794. View

12.

Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X . Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2009; 127(1):118-26. DOI: 10.1002/ijc.25007. View

13.

Graser A, Stieber P, Nagel D, Schafer C, Horst D, Becker C . Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population. Gut. 2008; 58(2):241-8. DOI: 10.1136/gut.2008.156448. View

14.

Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C . Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med. 2001; 7(3):297-303. DOI: 10.1038/85438. View

15.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

16.

Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T . Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem. 2010; 285(23):17442-52. PMC: 2878508. DOI: 10.1074/jbc.M110.107821. View

17.

Lieberman D . Clinical practice. Screening for colorectal cancer. N Engl J Med. 2009; 361(12):1179-87. DOI: 10.1056/NEJMcp0902176. View

18.

Kanaan Z, Rai S, Eichenberger M, Roberts H, Keskey B, Pan J . Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012; 256(3):544-51. DOI: 10.1097/SLA.0b013e318265bd6f. View

19.

Asangani I, Rasheed S, Nikolova D, Leupold J, Colburn N, Post S . MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene. 2007; 27(15):2128-36. DOI: 10.1038/sj.onc.1210856. View

20.

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View